TWiV 837: COVID-19 clinical update #91 with Dr. Daniel Griffin
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #91, Dr. Griffin discusses final results of molnupiravir trial, Omicron variant of concern, outcomes in B-cell depleted patients, recovery in T-cell depleted macaques, peptide for induction of T cell immunity, high respiratory viral RNA loads in infants, IgA and T cells transferred to breast milk after vaccination, sensitivity and specificity of ID NOW, post-acute sequelae at 12 months, disease in low and middle income countries.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Update on Molnupiravir results (Merck)
- Omicron (Wikipedia)
- P681H and IFN resistance (bioRxiv)
- Synthetic DMARDS and disease severity (Ann Rheum Dis)
- Recovery in T cell depleted macaques (mBio)
- T-cell inducing peptide (Nature)
- Respiratory viral RNA load in infants (J Inf Dis)
- IgA and T cells in breast milk (Cell Rep)
- ID NOW specificity and sensitivity (J Clinical Viral)
- Risk prediction algorithm (Thorax)
- PASC in adults at 12 months (Front Med)
- Letters read on TWiV 837
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]